← Back to Home

Personalized mRNA Vaccine for Pancreatic Cancer Shows Signs of Long-Term Survival in Immune Responders With Follow-Up of Up to Six Years

In a small trial involving 16 patients after surgery, 8 developed vaccine-induced immune responses, and 7 of those remained alive four to six years after surgery. The findings offer clues to durable anticancer immunity but do not yet prove that the vaccine can extend life or provide a cure.

By SURL BioNews

For patients undergoing pancreatic cancer surgery, reducing the risk of recurrence after tumor removal remains a challenge. A phase 1 trial of a personalized mRNA vaccine has extended follow-up to as long as six years after surgery: some patients retained vaccine-induced immune cells and also showed better long-term survival outcomes, providing a basis for further research into treatment after surgery.

These long-term data were presented by Vinod Balachandran of Memorial Sloan Kettering Cancer Center (MSK) in the United States at the 2026 American Association for Cancer Research (AACR) Annual Meeting, released by MSK in April, and reported by MDedge in May. Of the 16 vaccine recipients, 8 developed measurable vaccine-induced immune responses, and 7 of those remained alive four to six years after surgery. Among the other 8 patients, who had no measurable response, 2 remained alive, and median survival was 3.4 years. These figures describe survival status and cannot be directly interpreted to mean that all survivors remained free of recurrence.

The vaccine used in the trial, autogene cevumeran, was jointly developed by BioNTech and Genentech. The research team first analyzed genetic changes in each patient's tumor, then encoded information about selected tumor neoantigens into mRNA in an attempt to teach the immune system to recognize cancer cells. It is a therapeutic vaccine intended to help clear residual cancer cells after surgery and reduce the risk of recurrence, rather than to prevent cancer in healthy people.

The study also asks how long the induced immune response can last. According to MSK, vaccine-induced CD8+ T cells persisted in responders for up to six years. These cells can attack cancer cells; the long-term follow-up therefore provides evidence that the immune response is not merely transient. However, the continued presence of these cells does not itself mean that the cancer has been eradicated.

Earlier follow-up results from the same trial, published in *Nature* in 2025, offered clues about recurrence. At a median follow-up of 3.2 years, median recurrence-free survival had not yet been reached among the 8 immune responders, compared with 13.4 months among nonresponders, with a P value of 0.007 for the difference between the groups. However, 2 responders had experienced recurrence by that point, showing that an immune response does not guarantee that the disease will not return.

Interpreting these differences requires keeping the limitations of the trial design in view. In addition to surgery and the vaccine, patients received the immune checkpoint inhibitor atezolizumab and modified FOLFIRINOX chemotherapy. The study was small and had no randomized, unvaccinated control group. Grouping patients according to whether they developed an immune response after vaccination can reveal associations, but it cannot establish the vaccine's efficacy on its own, nor can the results be directly applied to patients with inoperable or metastatic disease.

MSK says a larger global phase 2 trial is underway. The next key step is to determine whether this immune response can be reproduced in more patients and translate into reliable benefits in recurrence and survival. At this stage, the study supports continued testing of personalized cancer vaccines, but proving a cure remains some way off.

References

  1. PravdaReport
  2. Memorial Sloan Kettering Cancer Center
  3. MDedge
  4. Nature